BC
ACAD icon

Birchview Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Birchview Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33M Hold
171,000
– – 2.02% 13
2026
Q1 		$3.81M Hold
171,000
– – 2.17% 12
2025
Q4 		$4.57M Hold
171,000
– – 2.67% 9
2025
Q3 		$3.65M Sell
171,000
-16,800
-9% -$397K 2.76% 9
2025
Q2 		$4.05M Sell
187,800
-75,600
-29% -$1.41M 4.02% 5
2025
Q1 		$4.38M Sell
263,400
-75,000
-22% -$1.36M 3.8% 3
2024
Q4 		$6.21M Sell
338,400
-62,000
-15% -$1M 5.05% 3
2024
Q3 		$6.16M Buy
400,400
+150,000
+60% +$2.5M 5.33% 3
2024
Q2 		$4.07M Hold
250,400
– – 3.76% 7
2024
Q1 		$4.63M Buy
250,400
+10,000
+4% +$248K 3.77% 5
2023
Q4 		$7.53M Hold
240,400
– – 5.89% 4
2023
Q3 		$5.01M Sell
240,400
-9,000
-4% -$244K 4.26% 5
2023
Q2 		$5.97M Hold
249,400
– – 4.48% 5
2023
Q1 		$4.69M Hold
249,400
– – 3.68% 6
2022
Q4 		$3.97M Hold
249,400
– – 2.8% 9
2022
Q3 		$4.08M Hold
249,400
– – 2.87% 6
2022
Q2 		$3.51M Buy
249,400
+50,000
+25% +$933K 2.56% 8
2022
Q1 		$4.83M Hold
199,400
– – 3.48% 5
2021
Q4 		$4.65M Hold
199,400
– – 3% 8
2021
Q3 		$3.31M Hold
199,400
– – 2.25% 10
2021
Q2 		$4.86M Buy
199,400
+22,400
+13% +$506K 2.91% 6
2021
Q1 		$4.57M Buy
177,000
+75,000
+74% +$3.3M 2.71% 6
2020
Q4 		$5.45M Hold
102,000
– – 3.14% 8
2020
Q3 		$4.21M Buy
102,000
+9,000
+10% +$389K 2.81% 6
2020
Q2 		$4.51M Buy
93,000
+1,000
+1% +$48K 2.72% 6
2020
Q1 		$3.89M Buy
92,000
+78,000
+557% +$3.21M 3.45% 5
2019
Q4 		$599K Hold
14,000
– – 0.44% 31
2019
Q3 		$504K Buy
14,000
+4,000
+40% +$121K 0.34% 29
2019
Q2 		$267K Buy
+10,000
New +$255K 0.16% 40

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Birchview Capital's ACAD Position: Q2 2026 in Review

Birchview Capital held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 171,000 shares worth $4.33M. The position accounts for 2.02% of the portfolio, ranked #13.

Birchview Capital first reported a position in ACAD in Q2 2019 and has held it in 29 quarters since. The position peaked at $7.53M in Q4 2023. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Birchview Capital held 171,000 shares of Acadia Pharmaceuticals worth $4.33M as of Q2 2026.
  • Birchview Capital left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
  • Acadia Pharmaceuticals made up 2.02% of Birchview Capital's portfolio in Q2 2026, its #13 holding.
  • Birchview Capital first reported a position in Acadia Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Birchview Capital's Acadia Pharmaceuticals position peaked at $7.53M in Q4 2023.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.